The company's protein engineering platform integrates technologies from machine learning, synthetic biology, and robotics to engineer protein drug properties, such as protease stability and tissue penetration, addressing unmet needs like Inflammatory Bowel Disease(IBD). LabGenius conducts its own experiments, using robotic automation and advanced machine learning, to design and critically learn from its results, enabling physicians to access protein therapeutics developed through this cutting-edge approach.